What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...